Oral desmopressin in nocturia with benign prostatic hyperplasia: A systematic review of the literature

Peer review under responsibility of Arab Association of Urology.

Figures & data

Fig. 1 Flowchart of the article selection process for the review.

Table 1 Characteristics of the included studies.

	References	Study type	No. of patients	Duration of treatment, months	AEs
1	Ahmed et al., 2015 [22]	RCT; desmopressin and tamsulosin vs tamsulosin alone	248	3	None
2	Bae et al. (2013) [9]	Desmopressin and tamsulosin vs tamsulosin alone	216	6	NA
3	Wang et al. (2011) [20]	RCT; desmopressin vs placebo	115	12	Not clinically significant hyponatraemia after 12 months
4	Berges et al. (2014) [14]	Observational, multicentre	137	3	Low incidence 2.2%
5	Chen et al. (2016) [16]	Retrospective	136	22–24	6.61% had AEs
6	Kim YW et al. (2015) [23]	Prospective multicentre study	54	3	NA
7	Kim JC et al. (2017) [17]	Desmopressin added to α-blockers	86	2	Mild
8	Cannon et al. (1999) [15]	Double-blind crossover	20	0.75	3 developed fluid retention
9	Mattiasson et al. (2002) [18]	Double-blind placebo	151	0.75	Mild adverse events.
10	Rezakhaniha et al. (2011) [19]	Desmopressin vs placebo	60	2	NA
11	Shin et al. (2014) [24]	Anticholinergic agent or antidiuretic agent as add-on therapy to an α-blocker	405	3	Four withdrew due to dizziness and hyponatraemia
12	Weiss et al. (2012) [7]	Desmopressin vs placebo based on dosing	757	1	Lower and gender-specific dosing to reduce hyponatraemia
13	Weiss et al. (2013) [10]	Desmopressin vs placebo based on dosing	385	3	Fewer hyponatraemia incidences
14	Kuo (2002) [13]	Desmopressin only	30	1	16.7% incidence
15	Song et al. (2014) [12]	Desmopressin only	68	27.9	Hyponatraemia incidence 4.4%
16	van Kerrebroeck et al. (2007) [21]	Desmopressin vs placebo	127	0.75	NA
17	Ho et al. (2005) [11]	Desmopressin alone	28	3	NA
18	Koca et al. (2012) [9]	Alfuzosin vs desmopressin with alfuzosin	49	3	NA

NA, not available.